Home › KBI Biopharma Selects Freeslate's Biologics Formulation System For Early And Late Stage Drug Development
 

Keywords :   


KBI Biopharma Selects Freeslate's Biologics Formulation System For Early And Late Stage Drug Development

2013-09-04 06:58:35| drugdiscoveryonline News Articles

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that KBI Biopharma, Inc. (KBI), a leading development and contract manufacturing organization serving the biopharmaceutical industry, has purchased Freeslate’s Biologics Formulation System to help develop more robust formulations using less time and material

Tags: system development early late

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.07Chattanooga Area High School Students Graduate from BASFs TECH Academy
02.07Atlantic Tropical Weather Outlook
02.07Fayette Pipe Transforms Black Steel Pipe with FayetteGuard
02.07Hurricane Beryl Graphics
02.07Hurricane Beryl Public Advisory Number 16A
02.07Summary for Hurricane Beryl (AT2/AL022024)
02.07Eastern North Pacific Tropical Weather Outlook
02.07Automotive Coatings to Reach $19B by 2028: MarketsandMarkets
More »